Clinical Research Studies in Pickup Family Neurosciences Institute
Participation in research and clinical investigation is an important commitment of Pickup Family Neurosciences Institute in its mission to provide patients access to leading-edge management and treatment for neurological disorders.
Hoag’s sub-specialized team of neuroscientists are actively involved in research to discover new therapies, drugs and other medical advancements to better the lives of patients suffering from neurological conditions. Pickup Family Neurosciences Institute is currently accepting patients to participate in a number of clinical research trials.
We offer a variety of clinical research studies in the following neurosciences therapeutic areas:
(171-18) Aadi, LLC ABI-009 GBM-007 nab-rapamycin for GBM: A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma
(Phase 2 study for patients who have a certain type of brain cancer.)
- (196-18) A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
(Phase 3 clinical trial, appropriate for patients with Lennox Gastaut Syndrome.)
- Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE)
(Study appropriate for patients with intractable mesial temporal lobe epilepsy)
Memory and Cognitive Disorders
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid
(Phase 3 study, appropriate for patients with preclinical Alzheimer’s disease and elevated amyloid and patients with early preclinical Alzheimer’s disease and intermediate amyloid.)
- A Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ)
(Phase 2 trial, appropriate for patients with early symptomatic Alzheimer’s disease.)
Mild Cognitive Impairment
- (162-19) Memory Improvement Through Nicotine Dosing (MIND) Study (MIND)
(Phase 2 clinical trial, appropriate for patients with mild cognitive impairment.)
- (157-20) Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)
(Phase 3 clinical trial, appropriate for patients with intracerebral hemorrhage.)
Your participation in any trial is entirely voluntary. You may decide to withdraw at any time without losing the benefits of your standard medical care.